Print

CellAct Pharma's Topoisomerase Inhibitor Demonstrates Success in Phase I Study Involving Adults With Heavily Pretreated Solid Tumors  
11/12/2012 10:22:29 AM

DORTMUND, Germany--(BUSINESS WIRE)--CellAct Pharma announced today that the company’s product candidate CAP7.1, a modification of the well-established anticancer agent etoposide, showed promising safety and tolerability following administration in adults with heavily pretreated solid tumors. In addition, signs of efficacy of CAP7.1 treatment were observed in the majority of treated patients, thereby indicating overall survival prolongation for patients with cancers of lung, hypopharnyx, ovarian, testicular, stomach, esophageal, biliary tract and neuroendocrine tumor of skin.
//-->